Literature DB >> 18990389

Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: "tap early and often" versus hospitalization.

John M Csokmay1, Belinda J Yauger, Melinda B Henne, Alicia Y Armstrong, John T Queenan, James H Segars.   

Abstract

OBJECTIVE: To compare the cost of two treatment regimens for moderate to severe ovarian hyperstimulation syndrome (OHSS): conservative inpatient versus outpatient management with paracentesis.
DESIGN: A decision-tree mathematical model comparing conservative inpatient versus outpatient management of moderate to severe OHSS was created. The common final pathway of either management was resolution of OHSS. Sensitivity analyses were performed over the range of variables. MAIN OUTCOME MEASURE(S): Total management cost of OHSS. RESULT(S): The cost of conservative therapy including first-tier complications was $10,099 (range $9,655-$15,044). The cost of outpatient management with paracentesis was $1954 (range $788-$12,041). This resulted in an estimated cost savings of $8145 with outpatient management with paracentesis. One-way sensitivity analyses were performed. Varying the probability of admission after outpatient treatment still indicated that outpatient treatment was the most cost-effective (probability = 1.0, cost = $6110). Varying the duration of hospitalization with primary inpatient treatment was equal to outpatient treatment costs only at a stay of 0.71 days or shorter. CONCLUSION(S): Our model suggests early outpatient paracentesis for moderate to severe OHSS is the most cost-effective management plan when compared with traditional conservative inpatient therapy. The cost savings for outpatient management persisted throughout a variety of outcome probabilities. Copyright 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2008        PMID: 18990389      PMCID: PMC3575958          DOI: 10.1016/j.fertnstert.2008.09.054

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  20 in total

Review 1.  Evaluating economic studies in reproductive medicine.

Authors:  Bradley J Van Voorhis
Journal:  Semin Reprod Med       Date:  2003-02       Impact factor: 1.303

Review 2.  Ovarian hyperstimulation syndrome: an update review.

Authors:  A Golan; R Ron-el; A Herman; Y Soffer; Z Weinraub; E Caspi
Journal:  Obstet Gynecol Surv       Date:  1989-06       Impact factor: 2.347

3.  Transcapillary fluid dynamics during ovarian stimulation for in vitro fertilization.

Authors:  A Tollan; N Holst; F Forsdahl; H O Fadnes; P Oian; J M Maltau
Journal:  Am J Obstet Gynecol       Date:  1990-02       Impact factor: 8.661

4.  An ounce of prevention: outpatient management of the ovarian hyperstimulation syndrome.

Authors:  M R Fluker; J E Copeland; A A Yuzpe
Journal:  Fertil Steril       Date:  2000-04       Impact factor: 7.329

Review 5.  Ovarian hyperstimulation syndrome: a current survey.

Authors:  J G Schenker; D Weinstein
Journal:  Fertil Steril       Date:  1978-09       Impact factor: 7.329

6.  Aggressive outpatient treatment of ovarian hyperstimulation syndrome with ascites using transvaginal culdocentesis and intravenous albumin minimizes hospitalization.

Authors:  Stephen R Lincoln; Michael S Opsahl; Keith L Blauer; Susan H Black; Joseph D Schulman
Journal:  J Assist Reprod Genet       Date:  2002-04       Impact factor: 3.412

7.  Ovarian hyperstimulation syndrome (OHSS): diagnosis and management.

Authors:  P Myrianthefs; C Ladakis; V Lappas; S Pactitis; A Carouzou; G Fildisis; G Baltopoulos
Journal:  Intensive Care Med       Date:  2000-05       Impact factor: 17.440

8.  Severe ovarian hyperstimulation syndrome: a reevaluated therapeutic approach.

Authors:  R Borenstein; U Elhalah; B Lunenfeld; Z S Schwartz
Journal:  Fertil Steril       Date:  1989-05       Impact factor: 7.329

Review 9.  Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review.

Authors:  Annick Delvigne; Serge Rozenberg
Journal:  Hum Reprod Update       Date:  2002 Nov-Dec       Impact factor: 15.610

10.  The incidence of both serious and minor complications in young women undergoing oocyte donation.

Authors:  Kara N Maxwell; Ina N Cholst; Zev Rosenwaks
Journal:  Fertil Steril       Date:  2008-02-04       Impact factor: 7.329

View more
  10 in total

Review 1.  Cost and efficacy comparison of in vitro fertilization and tubal anastomosis for women after tubal ligation.

Authors:  Lauren B Messinger; Connie E Alford; John M Csokmay; Melinda B Henne; Sunni L Mumford; James H Segars; Alicia Y Armstrong
Journal:  Fertil Steril       Date:  2015-05-23       Impact factor: 7.329

2.  A Sleeve-Sheath With a Coaxial Exchangeable Catheter for Palliative Evacuation of Recurrent Thoracic and Abdominal Effusions.

Authors:  Kevin Malone; Christopher M Stevens; Chandler Merriman; Daniel Harper; Reena Wadhwa; Horacio R D'agostino
Journal:  Cureus       Date:  2022-05-20

Review 3.  The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndrome.

Authors:  Lisa C Grossman; Konstantinos G Michalakis; Hyacinth Browne; Mark D Payson; James H Segars
Journal:  Fertil Steril       Date:  2010-09       Impact factor: 7.329

4.  Ovarian hyperstimulation syndrome: current views on pathophysiology, risk factors, prevention, and management.

Authors:  Michael M Alper; Laura P Smith; Eric Scott Sills
Journal:  J Exp Clin Assist Reprod       Date:  2009-06-10

5.  GnRH antagonist rescue in high responders at risk for OHSS results in excellent assisted reproduction outcomes.

Authors:  Micah J Hill; Rebecca J Chason; Mark D Payson; James H Segars; John M Csokmay
Journal:  Reprod Biomed Online       Date:  2012-05-23       Impact factor: 3.828

Review 6.  Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment.

Authors:  Klaus Fiedler; Diego Ezcurra
Journal:  Reprod Biol Endocrinol       Date:  2012-04-24       Impact factor: 5.211

7.  Evaluation of intravenous hydroxylethyl starch, intravenous albumin 20%, and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction.

Authors:  Ataollah Ghahiri; Neda Mogharehabed; Minoo Movahedi; Naeimehossadat Hosseini
Journal:  J Res Med Sci       Date:  2015-07       Impact factor: 1.852

8.  Patients with IVF complicated by moderate-to-critical OHSS experience increased thrombosis, GDM and neonatal NICU admission but slightly shorter gestation compared with matched IVF counterparts: A retrospective Chinese cohort study.

Authors:  Linli Hu; Rui Xie; Mengying Wang; Yingpu Sun
Journal:  Reprod Biol Endocrinol       Date:  2021-01-13       Impact factor: 5.211

9.  Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer-High Responder (MEGASET-HR) trial.

Authors:  Jared C Robins; Andrew F Khair; Eric A Widra; Michael M Alper; Winnie W Nelson; Eric D Foster; Anshul Sinha; Masakazu Ando; Patrick W Heiser; Gaurang S Daftary
Journal:  F S Rep       Date:  2020-11-10

10.  Outpatient Management of Severe Ovarian Hyperstimulation Syndrome (OHSS) with Placement of Pigtail Catheter.

Authors:  M Abuzeid; H Warda; S Joseph; M G Corrado; Y Abuzeid; M Ashraf; B Rizk
Journal:  Facts Views Vis Obgyn       Date:  2014
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.